Therapeutic hypothermia after pediatric cardiac arrest trials: the vanguard phase experience and implications for other trials.

Pemberton VL, Browning B, Webster A, Dean JM, Moler FW.

Source

1 Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. 2 Department of Pediatrics, Division of Critical Care, University of Utah, Salt Lake City, UT. 3 Department of Pediatrics, University of Michigan, Ann Arbor, MI.

Abstract

OBJECTIVE:

: To determine whether an 18-month vanguard phase, in the Therapeutic Hypothermia after Pediatric Cardiac Arrest trials, confirmed study feasibility and patient safety, a prerequisite to continued funding by the sponsor.

DESIGN:

: Randomized controlled trial.

SETTING:

: Pediatric intensive care and pediatric cardiac care units in 15 clinical sites in the United States and Canada.

PATIENTS:

: Children aged 48 hrs to 18 yrs of age, with return of circulation after cardiac arrest.

INTERVENTIONS:

: Therapeutic hypothermia vs. therapeutic normothermia.

MEASUREMENTS AND MAIN RESULTS:

: The first 15 of 20 potential sites to obtain Institutional Review Board and subcontract approvals were selected as vanguard sites. Institutional Review Board approvals were obtained 92 days (median, interquartile range 65-114) and subcontracts signed 34 days (interquartile range 20-48) after distribution. Sites screened subjects at 13 days (interquartile range 9-21) and enrolled the first subjects 64 days (interquartile range 13-154) after study launch. The recruitment milestone was reached 4 months ahead of schedule, with no safety concerns identified. Overall recruitment in this ongoing trial remains on target.

CONCLUSIONS:

: The Therapeutic Hypothermia after Pediatric Cardiac Arrest vanguard phase proved beneficial for the investigators and funding agency. Because complex multicenter trials are rarely ready to launch when grant funds are received, the vanguard allowed time to refine the protocol and recruitment approaches. Competition for vanguard positions led to expedient Institutional Review Board and subcontract completion. Early success and sustained momentum contributed to recruitment at or above goals. Financial risks to the sponsor were minimized by tying funding for the full trial to achieving prespecified milestones. A vanguard phase may be a desirable strategy for the successful conduct of other complex clinical trials.

CLINICAL TRIAL REGISTRATION:

: NCT00880087 and NCT00878644 (http://clinicaltrials.gov/ct2/show/NCT00880087?term=pediatric+hypothermia&rank=4; http://clinicaltrials.gov/ct2/show/NCT00878644?term=pediatric+hypothermia&rank=5).

PMID:: 23295834; [PubMed - in process]
PMCID:: PMC3540393; [Available on 2014/1/1]

NHLBI in the News

Pediatric Critical Care Medicine
Therapeutic hypothermia after pediatric cardiac arrest trials: the vanguard phase experience and implications for other trials
coauthored by Victoria L. Pemberton, R.N.C., M.S., Division of Cardiovascular Sciences
Read about the approach that the NHLBI used to support the Therapeutic Hypothermia after Pediatric Cardiac Arrest (THAPCA) trials and the lessons learned.

UCLA
Genes and obesity: Fast food isn't only culprit in expanding waistlines -- DNA is also to blame
Susan Thomas
In a new NHLBI-supported study, UCLA scientists discovered that body-fat responses to a typical fast-food diet are determined in large part by genetic factors, and they have identified several genes they say may control those responses.

Stanford University School of Medicine
Researchers use stem cells to pinpoint cause of common type of sudden cardiac death
Krista Conger
Stanford University School of Medicine researchers have identified the molecular basis for a condition called hypertrophic cardiomyopathy that is the most common cause for this type of sudden cardiac death.